AN2 Therapeutics Inc
NASDAQ:ANTX

Watchlist Manager
AN2 Therapeutics Inc Logo
AN2 Therapeutics Inc
NASDAQ:ANTX
Watchlist
Price: 1.09 USD 0.93%
Market Cap: 29.8m USD

Profitability Summary

AN2 Therapeutics Inc's profitability score is 26/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

26/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

26/100
Profitability
Score
26/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
AN2 Therapeutics Inc

Revenue
0 USD
Operating Expenses
-37.4m USD
Operating Income
-37.4m USD
Other Expenses
3.4m USD
Net Income
-34m USD

Margins Comparison
AN2 Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
AN2 Therapeutics Inc
NASDAQ:ANTX
29.8m USD N/A N/A
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
490.8B USD
27%
27%
CH
Roche Holding AG
SIX:ROG
249.1B CHF
34%
15%
UK
AstraZeneca PLC
LSE:AZN
215.5B GBP
24%
16%
CH
Novartis AG
SIX:NOVN
198.2B CHF
33%
26%
US
Merck & Co Inc
NYSE:MRK
251.7B USD
38%
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
42%
33%
IE
Endo International PLC
LSE:0Y5F
202B USD
11%
-126%
US
Pfizer Inc
NYSE:PFE
143.5B USD
29%
16%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
AN2 Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
AN2 Therapeutics Inc
NASDAQ:ANTX
29.8m USD
-46%
-41%
-51%
-1 326%
US
Eli Lilly and Co
NYSE:LLY
1T USD
97%
19%
42%
25%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
490.8B USD
33%
13%
18%
13%
CH
Roche Holding AG
SIX:ROG
249.1B CHF
33%
10%
31%
18%
UK
AstraZeneca PLC
LSE:AZN
215.5B GBP
22%
9%
18%
15%
CH
Novartis AG
SIX:NOVN
198.2B CHF
33%
14%
25%
18%
US
Merck & Co Inc
NYSE:MRK
251.7B USD
40%
15%
26%
21%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
71%
23%
57%
28%
IE
Endo International PLC
LSE:0Y5F
202B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
143.5B USD
11%
5%
11%
10%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less